A 2-gene panel derived from prostate cancer-enhanced transcripts in whole blood is prognostic for survival and predicts treatment benefit in metastatic castration-resistant prostate cancer

Authors :: Heck, MM
Thalgott, M
Schmid, SC
Oh, WK
Gong, Y
Wang, L
Zhu, J
Seitz, AK
Porst, D
Höppner, M
Retz, M
Gschwend, JE
Nawroth, R
Source :: 42. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie; 20160602-20160604; Augsburg; DOCFV44 /20160420/
Publication Year :: 2016
Publisher :: German Medical Science GMS Publishing House, 2016.
Abstract: Objective: To determine a prognostic model derived from prostate cancer-enhanced transcripts in whole blood of castration-resistant prostate cancer (CRPC) patients and explore its applicability as a surrogate of treatment response. Patients and methods: Six out of 23 selected transcripts were identified[for full text, please go to the a.m. URL]<br />42. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie

Language :: English
Database :: OpenAIRE
Journal :: 42. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie; 20160602-20160604; Augsburg; DOCFV44 /20160420/
Accession number :: edsair.doi.dedup.....2a9a5900ada9f898d01ab23bbbdba54f
Full Text :: https://doi.org/10.3205/16urobay044

Full Text Access

Tools